In PD mouse models, intracerebroventricular administration of LRRK2-targeted ASOs has been shown to decrease LRRK2 protein levels, reduce α-synuclein inclusions, and attenuate the degeneration of dopaminergic neurons in the substantia nigra (Zhao et al., 2017). Here, LRRK2 is linked to Parkinson disease.